Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Real-time Estimate Cboe BZX
Other stock markets
 02:02:45 2024-04-18 pm EDT 		5-day change 1st Jan Change
2.385 USD +0.21% Intraday chart for Lyell Immunopharma, Inc. -10.15% +23.20%
Mar. 04 North American Morning Briefing : Stock Futures -2- DJ
Feb. 28 Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Lyell Immunopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

69916b.RUGIKNddZCBGJUwEJRAJSP3CTZkyoQOsdQEOYddAQwY.CS3uR74CLmQxfHpPX3ZnMLiHHawLwmXCRGo8GbEvdDAyC9pFsAtQEQlEBQ~2d1beaf21b8e72bdb6f608c6d3d572d0

Analyst Recommendations on Lyell Immunopharma, Inc.

HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating MT
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15 MT
HC Wainwright Adjusts Price Target on Lyell Immunopharma to $9 From $11, Maintains Buy Rating MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating MT
Morgan Stanley Downgrades Lyell Immunopharma to Equalweight From Overweight, Adjusts Price Target to $7 From $15 MT
HC Wainwright Starts Lyell Immunopharma at Buy With $12 Price Target MT
Goldman Sachs Adjusts Price Target for Lyell Immunopharma to $12 From $21, Keeps Buy Rating MT
JPMorgan Lowers Price Target for Lyell Immunopharma to $15 From $22, Maintains Overweight Rating MT
Goldman Sachs Adjusts Lyell Immunopharma Price Target to $21 From $31, Maintains Buy Rating MT
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $20 from $25, Keeps Overweight Rating MT
LYELL IMMUNOPHARMA : JPMorgan Starts Lyell Immunopharma at Overweight With $22 Price Target MT
LYELL IMMUNOPHARMA : Morgan Stanley Starts Lyell Immunopharma at Overweight With $25 Price Target MT
LYELL IMMUNOPHARMA : BofA Securities Starts Lyell Immunopharma at Buy With $25 Price Target MT
LYELL IMMUNOPHARMA : Goldman Sachs Starts Lyell Immunopharma at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.38 USD
Average target price
6 USD
Spread / Average Target
+152.10%
High Price Target
9 USD
Spread / Highest target
+278.15%
Low Price Target
4 USD
Spread / Lowest Target
+68.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lyell Immunopharma, Inc.

HC Wainwright
JPMorgan Chase
Morgan Stanley
Goldman Sachs
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. Consensus Lyell Immunopharma, Inc.